Amundi lifted its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 42.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 69,871 shares of the medical device company’s stock after buying an additional 20,970 shares during the period. Amundi owned approximately 0.11% of Tandem Diabetes Care worth $2,619,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in the stock. Assetmark Inc. acquired a new position in Tandem Diabetes Care during the third quarter valued at $29,000. Crossmark Global Holdings Inc. acquired a new position in Tandem Diabetes Care during the third quarter valued at $200,000. State of New Jersey Common Pension Fund D lifted its position in Tandem Diabetes Care by 24.6% during the third quarter. State of New Jersey Common Pension Fund D now owns 44,776 shares of the medical device company’s stock valued at $1,899,000 after purchasing an additional 8,837 shares during the period. Los Angeles Capital Management LLC acquired a new position in Tandem Diabetes Care during the third quarter valued at $263,000. Finally, Victory Capital Management Inc. lifted its position in Tandem Diabetes Care by 45.6% during the third quarter. Victory Capital Management Inc. now owns 587,247 shares of the medical device company’s stock valued at $24,905,000 after purchasing an additional 183,877 shares during the period.
Tandem Diabetes Care Stock Performance
Shares of TNDM stock opened at $19.17 on Monday. The firm’s 50 day moving average price is $31.38 and its 200-day moving average price is $34.55. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. Tandem Diabetes Care, Inc. has a one year low of $17.64 and a one year high of $53.69. The firm has a market cap of $1.27 billion, a P/E ratio of -9.93 and a beta of 1.45.
Analyst Upgrades and Downgrades
Check Out Our Latest Analysis on TNDM
Insider Buying and Selling
In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos bought 10,538 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average cost of $18.12 per share, with a total value of $190,948.56. Following the purchase, the chief operating officer now directly owns 10,538 shares in the company, valued at approximately $190,948.56. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.20% of the stock is owned by insiders.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
Featured Articles
- Five stocks we like better than Tandem Diabetes Care
- 5 discounted opportunities for dividend growth investors
- How to Build the Ultimate Everything ETF Portfolio
- What is the Euro STOXX 50 Index?
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- The How and Why of Investing in Gold Stocks
- 3 Stocks With High ROE and Market-Beating Growth Potential
Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report).
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.